Back

Potent P2Y12 inhibitor monotherapy without aspirin early after percutaneous coronary intervention: the NEO-MINDSET Platelet Function Substudy

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Targeting platelets post-percutaneous coronary intervention Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Patricia Guimaraes

Einstein Hospital Israelita, Sao Paulo (Brazil)

6 More presentations in this session

Presentation thumbnail
Short-term DAPT followed by P2Y12 monotherapy versus standard-term DAPT after PCI for ACS: an updated systematic review and meta-analysis of randomised controlled trials
Associate Professor M. Monaghan (Enniskillen, GB)
Abstract Slides
Presentation thumbnail
Impact of age on comparative outcomes of abbreviated versus standard antiplatelet therapy in patients at high bleeding risk: a pre-specified analysis from the MASTER-DAPT trial
Doctor A. Landi (Lugano, CH)
Abstract Slides
Presentation thumbnail
Ticagrelor-based dual antiplatelet therapy versus aspirin monotherapy after CABG: a systematic review and meta-analysis of randomized controlled trials
Mr R. Goes (Asa Sul Brasilia, BR)
Abstract Slides
Presentation thumbnail
Differential prognostic value of platelet reactivity and CYP2C19 phenotype in high bleeding risk patients undergoing PCI: insights from the PTRG-DES Registry
Doctor J. Cha (Seoul, KR)
Abstract Slides
Presentation thumbnail
Clopidogrel versus aspirin for secondary prevention of coronary artery disease stratified by age: an individual patient data meta-analysis of 28,982 patients from 7 randomized trials
Doctor D. Giacoppo (Catania, IT)
Abstract Slides

Access the full session

Session thumbnail
Targeting platelets post-percutaneous coronary intervention

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Assessment of the antiplatelet effect of different p2y12 inhibitors using two methods at 30 and 120 minutes after oral loading in the cardiac catheterization laboratory
21 March 2026
thumbnail
Congress Presentation
Antiplatelet monotherapy in acute coronary syndromes: which patients and when
26 August 2023
thumbnail
Congress Presentation
Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study
1 September 2019
thumbnail
Congress Presentation
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome and multivessel coronary artery disease: a post-hoc analysis of the TROPICAL-ACS trial
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources